Education
About Us
Working with TipRanks
Follow Us
Immucell Corp. (ICCC)
NASDAQ:ICCC
Top Page
Immucell
(NASDAQ:ICCC)
53Neutral
Immucell (ICCC) vs. S&P 500 (SPY)
Market Cap
$48.15M
Dividend YieldN/A
Average Volume (3M)14.07K
Price to Earnings (P/E)―
Beta (1Y)-0.03
Revenue Growth51.63%
EPS Growth62.32%
CountryUS
Employees69
SectorHealthcare
Sector Strength77
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.28
Shares Outstanding8,982,623
10 Day Avg. Volume22,259
30 Day Avg. Volume14,075
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.84
Price to Cash Flow (P/CF)-17.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Immucell Business Overview & Revenue Model
Company DescriptionImmuCell Corporation (ICCC) is a biotechnology company that operates in the animal health sector. The company focuses on developing, manufacturing, and selling products that improve the health and productivity of dairy and beef cattle. Its core product, First Defense, is an orally delivered capsule that provides immediate immunity to newborn calves against common pathogens, helping to reduce the incidence of scours, a significant cause of mortality in calves.
How the Company Makes MoneyImmuCell primarily generates revenue through the sale of its proprietary product, First Defense, which is marketed to dairy and beef producers. The company's revenue model is based on direct sales and distribution partnerships that expand its market reach. ImmuCell also engages in research and development to innovate new products and improve existing ones, potentially creating additional revenue streams through expanded product offerings. Key factors contributing to earnings include market demand for effective animal health products, successful distribution partnerships, and maintaining a strong reputation in the industry for efficacy and reliability.
Immucell Financial Statement Overview
Summary
Immucell faces significant financial challenges, with operational losses and cash flow issues posing risks to its financial health. While the elimination of debt is a positive, inconsistent revenue growth and persistent negative profitability metrics indicate the need for strategic improvements to achieve financial stability.Income Statement
Immucell's revenue shows a mixed growth trajectory, with fluctuations over the past years. The gross profit margin is weak, and negative EBIT and net profit margins indicate struggles with profitability. Recent attempts to improve EBITDA show some hope, but consistent losses highlight significant operational challenges.45
Neutral
Balance Sheet
The company's balance sheet presents a moderate financial position with zero debt in the latest year, which reduces financial risk. However, the equity has been fluctuating, and negative total liabilities in the latest year present data inconsistencies. The equity ratio is strong, yet the company needs to ensure stability in its asset base.50
Neutral
Cash Flow
Immucell's cash flow has been under pressure with consistent negative free cash flow over the years. Operating cash flow has been volatile, and the inability to generate positive free cash flow suggests liquidity challenges. The absence of data in the latest year complicates the assessment.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 26.49M | 17.47M | 18.57M | 19.24M | 15.34M | Gross Profit |
| 7.94M | 4.40M | 7.65M | 8.66M | 6.86M | EBIT |
| -1.64M | -5.75M | -2.30M | -2.20M | -1.38M | EBITDA |
| 1.04M | -2.50M | 349.99K | 2.72M | 1.65M | Net Income Common Stockholders |
| -2.16M | -5.77M | -2.49M | -78.00K | -1.02M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 3.81M | 978.74K | 5.79M | 10.19M | 7.95M | Total Assets |
| 0.00 | 43.81M | 44.86M | 44.47M | 40.35M | Total Debt |
| 0.00 | 16.69M | 12.48M | 10.27M | 10.73M | Net Debt |
| 0.00 | 15.71M | 6.69M | 89.03K | 2.79M | Total Liabilities |
| -26.41M | 18.82M | 14.48M | 11.89M | 12.08M | Stockholders Equity |
| 26.41M | 24.99M | 30.38M | 32.58M | 28.27M |
| Cash Flow | Free Cash Flow | |||
| 0.00 | -6.57M | -5.52M | -1.65M | -2.76M | Operating Cash Flow |
| 0.00 | -4.67M | -1.54M | 954.17K | 1.32M | Investing Cash Flow |
| 0.00 | -1.89M | -3.96M | -1.60M | -2.57M | Financing Cash Flow |
| 0.00 | 1.75M | 1.11M | 3.88M | 1.91M |
Immucell Technical Analysis
Positive
5.38
Price Trends
5.11
Positive
4.85
Positive
4.35
Positive
Market Momentum
-0.06
Negative
43.53
Neutral
66.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ICCC, the sentiment is Positive. The current price of 5.38 is above the 20-day moving average (MA) of 4.99, above the 50-day MA of 5.11, and above the 200-day MA of 4.35, indicating a bullish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 43.53 is Neutral, neither overbought nor oversold. The STOCH value of 66.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ICCC.
Immucell Risk Analysis
Immucell disclosed 9 risk factors in its most recent earnings report. Immucell reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Immucell Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $48.15M | ― | -8.21% | ― | 51.63% | 62.32% | |
52 Neutral | $37.59M | ― | -51.22% | ― | -10.56% | 41.02% | |
49 Neutral | $40.30M | ― | -203.19% | ― | -85.35% | -178.92% | |
48 Neutral | $6.35B | 1.19 | -46.87% | 2.63% | 17.16% | 1.34% | |
46 Neutral | $42.51M | ― | -46.63% | ― | 4.58% | 10.59% | |
42 Neutral | $44.89M | ― | -203.16% | ― | -31.76% | 86.19% |
* Healthcare Sector Average
Performance Comparison
ICCC
Immucell
5.38
0.06
1.13%
IRD
Opus Genetics
0.85
-0.98
-53.55%
FBIO
Fortress Biotech
1.47
-0.43
-22.63%
BNR
Burning Rock Biotech
3.63
-3.48
-48.95%
RPTX
Repare Therapeutics
0.96
-3.08
-76.24%
Immucell Earnings Call Summary
Earnings Call Date: Feb 25, 2025 | % Change Since: 5.49% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Positive
The earnings call reflected a strong financial recovery for ImmuCell Corporation with significant sales growth, improved margins, and a positive EBITDA turnaround. However, historical production challenges and regulatory delays for the Re-Tain product were notable concerns. Overall, while there are areas needing improvement, the company's financial performance and strategic initiatives were largely positive.Highlights
Significant Sales Growth
ImmuCell Corporation reported a 52% sales growth during both the fourth quarter of 2024 and the full year 2024 compared to the previous year, achieving $7.8 million in sales during the fourth quarter.
Increase in Gross Margin
Gross margin increased by 125% to $2.8 million in Q4 2024 compared to Q4 2023, and by 105% to $7.9 million for the year ended December 31, 2024, compared to 2023.
Positive EBITDA Turnaround
The company generated EBITDA of $1.3 million in Q4 2024 compared to negative EBITDA of $311,000 in Q4 2023, marking a positive swing of approximately $3.7 million for the year.
Improved Cash Position
The company raised net proceeds of almost $4.4 million through at-the-market offering, improving its cash position to $3.8 million as of December 31, 2024, from $979,000 at the end of 2023.
Re-Tain Product Development
ImmuCell is poised to revolutionize subclinical mastitis treatment with Re-Tain, pending FDA clearance for a controlled launch, following significant investment and development.
Lowlights
Historical Production Challenges
The company faced production contamination events in 2023 and early 2024 that limited manufacturing output, leading to product supply shortages and backlog of orders.
Lower Than Target Gross Margin Percentage
Although the gross margin improved to 36.5% in Q4 2024, it is still below the company's target of over 40%, impacted by factors such as product mix and yield issues.
Regulatory Delays for Re-Tain
The launch of Re-Tain is pending FDA clearance of inspectional observations and review of submissions, delaying market entry despite long-term investment.
Company Guidance
During the call, ImmuCell Corporation reported significant improvements in its financial performance for the fourth quarter and the year ended December 31, 2024. The company achieved a 52% sales growth for both the quarter and the full year compared to the previous year, driven by overcoming earlier production challenges. Sales reached $7.8 million in the fourth quarter, suggesting an annual production capacity of $30 million or more. The gross margin improved to 36.5% in Q4, up from previous periods affected by contamination issues, with an aim to exceed 40%. EBITDA swung positively to $1.3 million in Q4 from negative $311,000 in the prior year, and $1.1 million for the year from negative $2.6 million in 2023, marking an improvement of $3.7 million. The company raised $4.4 million through an at-the-market offering, enhancing its cash position to $3.8 million by year-end. Additionally, ImmuCell is advancing its Re-Tain product towards FDA approval, with strategic options under consideration to offset development costs.Immucell Corporate Events
Executive/Board Changes
ImmuCell Appoints Timothy Fiori as New CFO
Positive
Apr 7, 2025
On April 7, 2025, ImmuCell Corporation announced the appointment of Timothy C. Fiori as its new Chief Financial Officer. Mr. Fiori brings 24 years of experience from Idexx Laboratories, where he held various financial and commercial roles. His appointment is seen as a strategic move to enhance ImmuCell’s growth, with expectations for him to improve financial systems and find efficiencies across the business.
Spark’s Take on ICCC Stock
According to Spark, TipRanks’ AI Analyst, ICCC is a Neutral.
Immucell Corporation shows some positive signs of recovery in its earnings call, with significant sales growth and improved margins. However, its financial performance remains challenged by operational losses and cash flow issues. Technical indicators show stability, but valuation metrics highlight profitability struggles. The company’s strategic initiatives offer potential, but risks remain from production challenges and regulatory delays.
To see Spark’s full report on ICCC stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.